Treeline Biosciences, Inc.

This early-phase study tests a new drug called TLN-372 in people with advanced solid tumors that have a KRAS mutation. The goal is to check the drug's safety and how well it works, both alone and with other cancer treatments. About 240 adults with measurable, advanced or metastat…

This early-stage trial is testing a new drug called TLN-121, alone or with other medicines, in about 180 people whose Non-Hodgkin Lymphoma has returned or stopped responding to prior treatments. The main goals are to check the drug's safety and how the body processes it, while al…

This early-phase trial tests an oral drug called TLN-254 in about 50 adults with relapsed or refractory T-cell lymphoma. The main goal is to see if the drug can shrink tumors and how safe it is. Participants take the drug by mouth on a set schedule, and researchers will monitor r…